Reduction in the risk of major adverse cardiovascular events with the BET protein inhibitor apabetalone in patients with recent acute coronary syndrome, type 2 diabetes, and moderate to high likelihood of non-alcoholic fatty liver disease
Background: Nonalcoholic fatty liver disease (NAFLD) is common among patients with type 2 diabetes mellitus (T2DM) and is associated with increased risk for coronary atherosclerosis and acute cardiovascular (CV) events. We employed the validated, non-invasive Angulo NAFLD fibrosis score (FS) in an i...
Main Authors: | Peter P. Toth, Gregory G. Schwartz, Stephen J. Nicholls, Aziz Khan, Michael Szarek, Henry N. Ginsberg, Jan O. Johansson, Kamyar Kalantar-Zadeh, Ewelina Kulikowski, Ken Lebioda, Norman C.W. Wong, Michael Sweeney, Kausik K. Ray |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-09-01
|
Series: | American Journal of Preventive Cardiology |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2666667722000563 |
Similar Items
-
Bromodomain and Extraterminal Protein Inhibitor, Apabetalone (RVX-208), Reduces ACE2 Expression and Attenuates SARS-Cov-2 Infection In Vitro
by: Dean Gilham, et al.
Published: (2021-04-01) -
Apabetalone Downregulates Fibrotic, Inflammatory and Calcific Processes in Renal Mesangial Cells and Patients with Renal Impairment
by: Dean Gilham, et al.
Published: (2023-06-01) -
The BET inhibitor apabetalone decreases neuroendothelial proinflammatory activation in vitro and in a mouse model of systemic inflammation
by: Wasiak Sylwia, et al.
Published: (2023-12-01) -
Epigenetic Modifiers as Potential Therapeutic Targets in Diabetic Kidney Disease
by: Julio M. Martinez-Moreno, et al.
Published: (2020-06-01) -
Apabetalone, a Clinical-Stage, Selective BET Inhibitor, Opposes DUX4 Target Gene Expression in Primary Human FSHD Muscle Cells
by: Christopher D. Sarsons, et al.
Published: (2023-09-01)